Maintenance Notice

Due to necessary scheduled maintenance, the JMIR Publications website will be unavailable from Wednesday, July 01, 2020 at 8:00 PM to 10:00 PM EST. We apologize in advance for any inconvenience this may cause you.

Who will be affected?

Accepted for/Published in: JMIR Research Protocols

Date Submitted: May 15, 2022
Open Peer Review Period: May 15, 2022 - May 19, 2022
Date Accepted: May 26, 2022
(closed for review but you can still tweet)

The final, peer-reviewed published version of this preprint can be found here:

Development of a Patient-Centered Preference Tool for Patients With Hematologic Malignancies: Protocol for a Mixed Methods Study

Cole A, Richardson DR, Adapa K, Khasawneh A, Crossnohere NL, Bridges JF, Mazur L

Development of a Patient-Centered Preference Tool for Patients With Hematologic Malignancies: Protocol for a Mixed Methods Study

JMIR Res Protoc 2022;11(6):e39586

DOI: 10.2196/39586

PMID: 35767340

PMCID: 9280452

Warning: This is an author submission that is not peer-reviewed or edited. Preprints - unless they show as "accepted" - should not be relied on to guide clinical practice or health-related behavior and should not be reported in news media as established information.

Development of a patient-centered preference tool for patients with hematologic malignancies: protocol for a mixed methods study

  • Amy Cole; 
  • Daniel R. Richardson; 
  • Karthik Adapa; 
  • Amro Khasawneh; 
  • Norah L. Crossnohere; 
  • John F.P. Bridges; 
  • Lukasz Mazur

ABSTRACT

Background:

The approval of novel therapies for patients diagnosed with hematologic malignancies have improved survival outcomes but increased the challenge of aligning chemotherapy choices with patient preferences. A primary role of oncologists is to inform patients of their treatment options while assessing their preferences for risks and benefits of therapy. We previously developed paper versions of a discrete choice experiment (DCE) and a best worse scaling (BWS) instrument to quantify the treatment outcome preferences of patients with hematologic malignancies.

Objective:

We aim to develop an electronic healthcare tool (EHT) to guide clinical decision-making that uses either a BWS or DCE instrument to capture patient preferences. The primary objective of this study is to use both qualitative and quantitative methods to evaluate the perceived usability, CWL, and performance of electronic prototypes that include the DCE and BWS instrument. This evaluation will inform the development of EHTs to be used clinically with patients and providers.

Methods:

This mixed-methods study includes iterative co-design methods that will involve healthy volunteers, patient-caregiver pairs, and healthcare workers in both qualitative and quantitative assessments to evaluate the perceived usability, CWL and performance of tasks within distinct prototypes.

Results:

Enrollment of participants for this study is underway and expected to be complete by the fall of 2022.

Conclusions:

Our findings will help differentiate the usability, CWL, and performance of the DCE and BWS within the prototypes.


 Citation

Please cite as:

Cole A, Richardson DR, Adapa K, Khasawneh A, Crossnohere NL, Bridges JF, Mazur L

Development of a Patient-Centered Preference Tool for Patients With Hematologic Malignancies: Protocol for a Mixed Methods Study

JMIR Res Protoc 2022;11(6):e39586

DOI: 10.2196/39586

PMID: 35767340

PMCID: 9280452

Download PDF


Request queued. Please wait while the file is being generated. It may take some time.

© The authors. All rights reserved. This is a privileged document currently under peer-review/community review (or an accepted/rejected manuscript). Authors have provided JMIR Publications with an exclusive license to publish this preprint on it's website for review and ahead-of-print citation purposes only. While the final peer-reviewed paper may be licensed under a cc-by license on publication, at this stage authors and publisher expressively prohibit redistribution of this draft paper other than for review purposes.